top of page
Search

CEO DROPS A BIG SACK ON OWN SHARE BUY BACK

📢 CRISPR THERAPEUTICS (CRSP)


SKYROCKETS ~18% AFTER BOARD DIRECTOR BUYS $51M IN STOCK 🚀🎉

THAT KIND OF INSIDER MOVE? MEANS THE CEO BELIEVES BIG IN HIS COMPANY 📈💪!


🧬 WHAT IS CRISPR?


IT’S A COOL BIOTECH COMPANY THAT USES GENE-EDITING TECH (CRISPR/Cas9) TO DEVELOP MEDICINES FOR SICKLE-CELL, THALASSEMIA & MORE. THEY’VE GOT ONE FDA-APPROVED THERAPY (EXA-CEL) AND A TON OF OTHER DRUGS IN THE PIPELINE 🧪✨


📊 FUNDAMENTALS AT A GLANCE:


  • P/E ratio: NEGATIVE (~–14) THEY’RE LOSING MONEY RIGHT NOW  .

  • P/B ratio: ~2–3× (reasonably valued relative to assets)  .

  • P/S ratio: CRAZY HIGH (~85×) — REVENUE IS SMALL  .

  • Margins: SUPER UNPROFITABLE: NEGATIVE GROSS, OPERATING, NET MARGINS — THEY’RE SPENDING HEAVILY TO DEVELOP DRUGS  .

  • ROE/ROA/ROI: ALL NEGATIVE (~–20%); STILL LOSING MONEY ON INVESTED CAPITAL  .

  • Free Cash Flow: GROWING, BUT STILL NEGATIVE  .

  • Debt-to-equity: LOW (~0.3–0.6)—so debt isn’t choking them  .

  • Growth: REVENUE GROWTH STRONG (~28% CAGR; forecasted 122% next 3 years) 


📈 PRICE ACTION:


STOCK SURGED ~18–21% RECENTLY, HITTING 52-WEEK HIGHS, AS INSIDER BUYING SUPERCHARGED SENTIMENT  .


👥 ANALYST OPINION:


  • CONSENSUS = MODERATE BUY.

  • PRICE TARGETS RANGE: LOW ~$32 → HIGH ~$281 ; AVG ~$82–$82.5 — SUGGESTING ~25–30% UPSIDE  .

  • EXAMPLE: HC Wainwright INITIATED A BUY; MARKETBEAT = MODERATE BUY (10 Buys, 6 Holds, 1 Sell)  .


🏅 BIG NAMES & WHO’S BUYING:


  • Simeon George (director) dropped $51.5M of his own cash—huge confidence play  .

  • Institutional holders like ARK Innovation (ARKG) also own large stakes via popular biotech funds  .


🕒 PAST PERFORMANCE:


  • UP ~7–16% YTD, beating broader market in recent months  .

  • VOLATILE (beta ~1.8), but trending up since Q1  .


💡 WHAT’S THE BOTTOM LINE FOR YOU?


  • PROS: HUGE growth potential in gene editing, insiders buying BIG, and strong analyst sentiment.

  • CONS: Still losing money, sky-high ratios, and vulnerable if drug trials or regulations flop.

  • WHO IT’S FOR: High-risk, high-reward biotech fans. Not for the faint of heart.

  • BEST MOVE: If you’re into biotech and believe in CRISPR’s future, this might be your moonshot. Otherwise, it’s a volatile bet — so only invest what you’re cool losing.


SUMMARY IN ONE LINE:


🧬 CRSP IS A BOLD BIOTECH BET — INSIDER BUY & ANALYSTS SAY BUY, BUT VALUATION IS EXTREME & PROFITS ARE STILL MISSING! 🤯

Comments

bottom of page